NEWS
Free Institutional Consultancy Services
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 220 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
login
Login
person_add
Register
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Nadeem Ahmad Vellore
University of Utah - Salt Lake City / United States
Natural Sciences / Chemical Sciences
AD Scientific Index ID: 1681827
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Nadeem Ahmad Vellore's MOST POPULAR ARTICLES
1-)
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemiaMS Zabriskie, CA Eide, SK Tantravahi, NA Vellore, J Estrada, FE Nicolini, ...Cancer Cell 26 (3), 428-442, 20143112014
2-)
Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutantsCA Eide, MS Zabriskie, SLS Stevens, O Antelope, NA Vellore, H Than, ...Cancer cell 36 (4), 431-443. e5, 20191732019
3-)
A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancerA Drilon, R Somwar, JP Wagner, NA Vellore, CA Eide, MS Zabriskie, ...Clinical Cancer Research 22 (10), 2351-2358, 20161712016
4-)
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiaAM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ...Leukemia 31 (5), 1253-1254, 20171592017
5-)
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemiaAM Eiring, BDG Page, IL Kraft, CC Mason, NA Vellore, D Resetca, ...Leukemia 29 (3), 586-597, 20151452015
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept